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Viruses from several families are being
developed and tested clinically as
oncolytic agents for selected cancers.
The use of viruses as oncolytic agents
for cancer therapy (virotherapy) was first
described several decades ago, using a
variety of viruses, including adenovirus
(Ad), influenza virus, mumps virus, and
Newcastle disease virus (NDV), in a
number of diverse indications (reviewed
in Kirn et al., 2000; Stanziale and Fong,
2003). Although sporadically successful,
this field lay essentially dormant for
many years, but received a kick-start
with the application of two DNA viruses,
first herpes simplex virus (HSV) and then
Ad, having deletions in genes that con-
ferred specificity for cancer cells. While
response rates in early clinical trials have
been encouraging, there still are no
phase III clinical trials with any oncolytic
viruses. Thus, while the concept of virus-
es that propagate selectively within
tumor cells is tantalizing, there continues
to be ample room in the field for novel
approaches in order for oncolytic viruses
to become a major paradigm of cancer
therapy.
In this issue of Cancer Cell, John
Bell, David Stojdl, and colleagues (Stojdl
et al., 2003) present exciting results with
a relatively new player in the virotherapy
field: vesicular stomatitis virus (VSV), an
enveloped virus containing a single-
stranded RNA genome. Particular VSV
mutants showed a dramatic preference
for productive infection in tumor cells, as
compared to normal interferon (IFN)-
responsive cells. The VSV mutant strains
could be administered systemically to
athymic or immunocompetent mice bear-
ing human tumor xenografts or dissemi-
nated tumors and confer significant
long-term durable survival, importantly
without treatment-associated toxicity.
Historically, many RNA viruses were
tested clinically as cancer therapeutics
(Russell, 2002). More recently, their use
lagged behind work with DNA viruses,
perhaps in part due to poor understand-
ing of how the natural biology of RNA
viruses could be exploited to target can-
cerous cells. A key to preferential replica-
tion was the discovery that cancer cells
commonly acquire defects in IFN-α/β
signaling pathways, a frontline innate
response that host cells utilize to combat
viral infection. Through dsRNA interme-
diates, infection by both DNA and RNA
viruses induces host cells to produce
interferon and both have evolved mecha-
nisms to inhibit the effects of IFN induc-
tion. RNA viruses, such as VSV, are far
more sensitive to the antiviral activity of
IFN induction. Over time, it became con-
ceptually apparent that the defective
interferon response in cancer cells pre-
sented a therapeutic window for oncolyt-
ic RNA virus therapy. Previous work by
the authors of this manuscript and by
others have demonstrated both the effi-
cient lytic growth of VSV in several
human tumor cell types and the potent
antitumor efficacy of unmodified VSV in
both immune-competent and xenograft
models (Huang et al., 2003; Balachandran
and Barber, 2000; Stojdl et al., 2000).
What VSV-mediated virotherapy has
lacked to date—an effective oncolytic
agent with a therapeutic window big
enough to allow systemic administra-
tion—has been addressed in this investi-
gation. The breakthrough resulted from
characterizing the underlying mecha-
nisms by which VSV combats the host
innate antiviral response. The biologic
properties of three VSV mutants, AV1,
AV2, and AV3 (Desforges et al., 2001),
each having a small plaque phenotype in
interferon-responsive cells, were com-
pared to wild-type VSV. The AV variants
are all mutants of the viral M gene, which
encodes one of the structural proteins
that constitute the enveloped “coat.”
Compelling data are presented demon-
strating that the AV mutants are powerful
inducers of the host antiviral response:
(1) supra-high levels of IFN-α were
induced following infection of epithelial
cells; (2) primary mouse embryo fibrob-
lasts (MEFs) were refractory to infection
with the VSV variants (while MEFs were
refractory to infection with wild-type VSV
only when interferon was added exoge-
nously); and (3) high levels of systemic
IFN-α were also observed in mice inject-
ed with the AV mutants. Furthermore, co-
administration to mice of an AV variant
dramatically lowered the toxicity of wild-
type VSV, presumably due to induction of
protective levels of interferon by the VSV
M protein mutants. The AV variants and
wild-type VSV were equally toxic in Type
1 IFN receptor knockout mice, demon-
strating the requirement for an intact
interferon signaling system in order for
the AV mutant phenotypes to be
revealed. Taken together, these experi-
ments demonstrated that unlike wild-
type virus, high levels of the VSV
variants could in fact be safely adminis-
tered to mice systemically. As wild-type
VSV is neurovirulent in mice, the mutant
strains utilized in this investigation
should have a major impact on pre-clini-
cal development of VSV virotherapy. An
alternative approach with a similar result
was recently reported by Glen Barber
and colleagues (Obuchi et al., 2003),
demonstrating that recombinant VSV
encoding IFN-β was nonlytic in normal
human cells, but highly productive for
growth in tumor cells, and could be given
safely to tumor-bearing immunocompe-
tent animals by intravenous administra-
tion, resulting in significant antitumor
efficacy.
Why do the AV mutants induce high
levels of IFN-α production within interfer-
on-responsive cells? The investigators
addressed this question through a com-
bination of microarray and RT-PCR
analyses of infected cells. The induction
of essential transcription factors, like
IRF-3 (together with NF-κB and c-
JUN/ATF-2), which triggers the activation
of antiviral responses, was equivalent in
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Vesicular stomatitis virus: An exciting new therapeutic oncolytic
virus candidate for cancer or just another chapter from Field’s
Virology?
Selected mutant strains of vesicular stomatitis virus (VSV) are described that are unable to combat endogenous IFN-β sig-
naling within infected normal cells and as a result are dramatically more selective for productive growth in tumor cells hav-
ing a defective antiviral response. The VSV mutants may have the potential to be used clinically as a systemic oncolytic
agent for the treatment of distal and metastatic cancers.
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cells infected with either wild-type VSV or
the AV variants. In contrast, the level of
IFN-β message in the cytoplasm (and
production of IFN-β protein) was striking-
ly lower in cells infected with wild-type
VSV. This result suggests that the native
VSV M protein somehow prevents trans-
port of IFN-β mRNA to the cytoplasm;
indeed, other investigators have shown
that VSV M protein does in fact complex
with the nuclear pore proteins, suggest-
ing a possible mechanism in which M
“clogs” the nuclear pore (Petersen et al.,
2000). In turn, autocrine and paracrine
signaling by IFN-β through the JAK/STAT
pathway activates IRF-7 and the produc-
tion of IFN-α. Based on comparative
microarray analyses from wild-type VSV
and AV mutant infected cells, the authors
propose a model for an antiviral
response cascade, in which IFN-β is an
integral “gatekeeper” that activates (via
IRF-7) induction of a full tertiary antiviral
response, including production of IFN-α.
According to this model, unlike wild-type
VSV, the AV mutants are unable to sup-
press production of IFN-β, and full induc-
tion of the antiviral response occurs,
resulting in a “cytokine cloud” that pro-
tects normal surrounding tissue in the
host.
It is now clear that defects in IFN sig-
naling pathway are common among cells
from diverse cancer types. In part, the
selection for these defects appears to
result from a resistance to induction of
apoptosis. Other selection pressures
may be operable as well: induction of
type I IFN leads to induction of IFN-γ and
upregulation of class I molecules—the
precise response that tumor cells don’t
want in the face of ever-vigilant immuno-
surveillance. Thus, IFN-β signaling
seems to play an essential role in both
the innate antiviral as well as the adap-
tive immune response: signaling through
the JAK/STAT pathway by IFN-β pro-
motes the antiviral response to directly
attenuate virus infection through activa-
tion of PKR and RNase L (Balachandran
et al., 2000); activation of IFN-α and sub-
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Table 1. Selected RNA virus clinical trials
Parental virus Strain name Indication Trial Regimen Results Toxicity Ref.
Reovirus REOLYSIN Advanced cancer I (n = 18) 1 × 1071 × 1010 PFU Rising antibody titers in all pts Grade 2 or less; 1, 2
with palpable lesions intralesional single transient flu-like
versus 3 × (q2d) symptoms, 
headache
1 CR and 1 PR (local lesion)
REOLYSIN T2 Prostate I (n = 45) Single intralesional Viral activity in 5 of 6 treated No AEs or DLTs 3
ongoing injection prior to resection patients; limited to cancerous
lesion
REOLYSIN Recurrent glioma I/II Single intra-lesional, 4 of six treated patients alive Well tolerated 4
image-guided surgery at end of 6 month follow-up
period
Newcastle Ulster Colorectal liver I/II Oncolysate vaccine Increase in recurrence-free  Transient 5
disease virus mets (n = 23) interval; elevated 
(NDV) no impact on survival temperature
MTH-68/N Advanced cancer I/II (n = 33) 4000U/day inhalation 8 PR Fever in 8/33 6
PV701 Advanced solid I (n = 79) 5.924 × 109 14 SD, 1 CR, 1 PR Fever, flu-like 7 
cancer PFU/m2 (IV) syndrome,
leucopenia, 
thrombo-
cytopenia,
increase in liver 
enzymes, 
diarrhea
PV701 Advanced cancer 11 3 week cycle of Of 8 evaluable pts, 3 hr IV: fever, 8
ongoing enrolled 6 doses/2 wks 2 PR, 3 SD, 1 PD hypotension, 
3 hr IV (dose fatigue and chills 
1;12 × 109 PFU) versus 1 hr 1 hr IV: tumor
IV (dose 26; site AE, 
24120 × 109 PFU) inflammation
PV701 Peritoneal cancers No report Determine optimal first IV No report 9
ongoing dose (desensitizing) and 
MTD of IP treatment dose
Measles virus TC-adapted Advanced cancers n = 90 IV, IT, PO, rectal, 37/90 treated with >50% Febrile 10
(MV-Ed) MV strain or inhalation reduction in tumor burden reactions
Gynecological n = 22 Priming SC (1 × 108 PFU), Response limited to local MV 11
cancers followed by IP or delivery of primed patients
intrathoracic (1 × 109 PFU)
Abbreviations: PO, oral administration; IV, intravenous; IT, intraperitoneal; CR, complete response; PR, partial response; SD, stable disease; q2d, every other
day; AE, adverse event; DLT, dose-limiting toxicity.
1Morris et al. (2002). ASCO abstract and presentation #92; 2Coffey et al. (1998). Science 282, 13321334; 3Morris et al. (2003). Presented at Oncolytic Viruses
as Cancer Therapeutics, 28 March 2003, Banff, Alberta; 4http://www.Oncolyticsbiotech.com; 5Schlag et al. (1992). Cancer Immunol. Immun. 35, 325330;
6Csatary et al. (1993). Cancer Detect. Prev. 17, 619627; 7Pecora et al. (2002). J. Clin. Oncol. 20, 22512266; 8Hotte et al. (2003). ASCO abstract and presen-
tation #791; 9Spriggs (2003). http://www.clinicaltrials.gov.; 10Asada (1974). Cancer 34, 19071928; 11Shimizu (1988). Cancer Detect. Prev. 12, 487495.
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sequent IFN-γ expression facilitates the
adaptive immune response. It turns out
that viruses are not unique in activating
the production of IFN-β. Our laboratory is
utilizing genetically defined attenuated
mutants of the facultative intracellular
bacterium, Listeria monocytogenes, to
deliver antigens related to infectious and
malignant disease. It was recently
demonstrated that productive cytosolic
propagation during Listeria infection is
accompanied by host cell production of
IFN-β (O’Riordan et al., 2002). Since
protection against Listeria infection is
mediated by CD4+/CD8+ T cells, it is rea-
sonable to speculate that the production
of IFN-β in response to both viral and
Listeria infection is an innate mechanism
to alert the adaptive immune response.
How have RNA viruses fared clinical-
ly? There have been multiple phase I/II
clinical trials using RNA viruses from
diverse families, and other clinical trials
are planned (reviewed in Russell, 2002;
Table 1). Only NDV, and to a lesser
extent measles virus, have been safely
administered intravenously. Both of
these systemic virotherapies have
reported objective responses across a
wide range of solid tumors, importantly
without acute toxicity. While encourag-
ing, a fully controlled efficacy trial that is
sufficiently powered will be required to
determine whether the clinical respons-
es with any of the RNA oncolytic viruses
are significant. As has been shown with
Ad, combination with either established
chemotherapy regimens and/or radiation
may significantly augment the efficacy of
oncolytic RNA viruses.
Finally, is the notion of VSV as an
oncolytic agent simply another chapter—
among many—out of Field’s Virology?
The answer would appear to be certainly
not. While it is too early to tell whether
VSV will be effective clinically, it is clear
that RNA viruses have many desirable
features compared to Ad and HSV. For
example, the comparatively short repro-
ductive cycle of VSV could translate into
high viral titers in the tumor microenvi-
ronment and broad lytic infection
throughout the tumor. By understanding
the mechanisms through which VSV
combats the antiviral response, Stojdl
and colleagues have developed a VSV
variant with a sufficient degree of prefer-
ential replication in tumor cells to permit
systemic delivery and treatment of
metastatic disease. Additional improve-
ments may still be needed (e.g., system-
ically administered VSV may be
inactivated by human serum; DePolo et
al., 2000), and virus-neutralizing immune
responses upon repeated administration
remains to be a key issue for virotherapy.
Nevertheless, VSV mutant strains
unable to prevent the IFN-β-mediated
signaling of host cell innate antiviral
responses represent a promising new
therapeutic oncolytic virus candidate.
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